A hazard ratio of 0.53 against best supportive care is a meaningful signal in a tumor type where, after exhausting PARP inhibitors and bevacizumab, median progression-free survival barely clears eight weeks. That is the baseline the TEDOVA trial was designed to beat — and the Tedopi plus pembrolizumab combination did beat it, extending median PFS from 2.8 to 4.1 months in 185 platinum-sensitive recurrent ovarian cancer patients. The absolute gain looks modest in isolation. In context, it represents the first positive randomized maintenance trial in this population in years, and the first proof-of-concept for a neoantigen peptide vaccine strategy in ovarian cancer.
The trial’s 1:1:2 randomization was deliberate. Arm C — the combination — was powered as the primary comparison against supportive care, and it cleared statistical significance at p<0.001. The monotherapy arm versus combination arm comparison produced an HR of 0.72 with a p-value of 0.074, which is numerically interesting but not significant at conventional thresholds. That gap matters for how OSE frames the next development step. Tedopi monotherapy showed biological activity; pembrolizumab amplified it. The combination's immune-related adverse event profile was consistent with what anti-PD-1 therapies predictably produce, so there is no unexpected safety signal disrupting the narrative here.
What makes this data set strategically consequential is what it does for OSE’s broader Tedopi program. The asset already has Phase 3 ambitions in non-small cell lung cancersmall cell lung cancer, where it holds HLA-A2-restricted neoantigen targeting. TEDOVA now provides a second tumor type with randomized evidence, which strengthens the mechanistic argument that the vaccine platform can prime T-cell responses in heavily pretreated patients across histologies — not a tumor-specific accident. That kind of cross-indication validation is rare at Phase 2 and changes the risk calculus for a potential partnership or licensing conversation. OSE is a small Euronext-listed company running largely academic-sponsored trials; the asset’s value relative to its development cost is increasingly difficult to ignore.
The number to watch when full data is presented at ASCO on May 30 is the disease control rate stratified by HLA-A2 status. Tedopi’s mechanism is HLA-A2 restricted, and if the PFS benefit concentrates in that subgroup — which TEDOVA’s enrollment criteria should have partially controlled for — it defines both the addressable patient population and the biomarker framework a Phase 3 ovarian cancer trial would need to be built around.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
